Differences in human papillomavirus type distribution in high-grade cervical intraepithelial neoplasia and invasive cervical cancer in Europe
- PMID: 22752992
- DOI: 10.1002/ijc.27713
Differences in human papillomavirus type distribution in high-grade cervical intraepithelial neoplasia and invasive cervical cancer in Europe
Abstract
Knowledge of differences in human papillomavirus (HPV)-type prevalence between high-grade cervical intraepithelial neoplasia (HG-CIN) and invasive cervical cancer (ICC) is crucial for understanding the natural history of HPV-infected cervical lesions and the potential impact of HPV vaccination on cervical cancer prevention. More than 6,000 women diagnosed with HG-CIN or ICC from 17 European countries were enrolled in two parallel cross-sectional studies (108288/108290). Centralised histopathology review and standardised HPV-DNA typing were applied to formalin-fixed paraffin-embedded cervical specimens dated 2001-2008. The pooled prevalence of individual HPV types was estimated using meta-analytic methods. A total of 3,103 women were diagnosed with HG-CIN and a total of 3,162 with ICC (median ages: 34 and 49 years, respectively), of which 98.5 and 91.8% were HPV-positive, respectively. The most common HPV types in women with HG-CIN were HPV16/33/31 (59.9/10.5/9.0%) and in ICC were HPV16/18/45 (63.3/15.2/5.3%). In squamous cell carcinomas, HPV16/18/33 were most frequent (66.2/10.8/5.3%), and in adenocarcinomas, HPV16/18/45 (54.2/40.4/8.3%). The prevalence of HPV16/18/45 was 1.1/3.5/2.5 times higher in ICC than in HG-CIN. The difference in age at diagnosis between CIN3 and squamous cervical cancer for HPV18 (9 years) was significantly less compared to HPV31/33/'other' (23/20/17 years), and for HPV45 (1 year) than HPV16/31/33/'other' (15/23/20/17 years). In Europe, HPV16 predominates in both HG-CIN and ICC, whereas HPV18/45 are associated with a low median age of ICC. HPV18/45 are more frequent in ICC than HG-CIN and associated with a high median age of HG-CIN, with a narrow age interval between HG-CIN and ICC detection. These findings support the need for primary prevention of HPV16/18/45-related cervical lesions.
Copyright © 2012 UICC.
Similar articles
-
Distribution of human papillomavirus genotypes in cervical intraepithelial neoplasia and invasive cervical cancer in Canada.J Med Virol. 2011 Jun;83(6):1034-41. doi: 10.1002/jmv.22081. J Med Virol. 2011. PMID: 21503917
-
Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer.Int J Cancer. 2012 Nov 15;131(10):2349-59. doi: 10.1002/ijc.27485. Epub 2012 Mar 20. Int J Cancer. 2012. PMID: 22323075
-
Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence.J Natl Cancer Inst. 2010 Oct 6;102(19):1478-88. doi: 10.1093/jnci/djq356. Epub 2010 Sep 14. J Natl Cancer Inst. 2010. PMID: 20841605 Free PMC article.
-
Prevalence and distribution of human papillomavirus genotypes in cervical intraepithelial neoplasia in China: a meta-analysis.Arch Gynecol Obstet. 2020 Dec;302(6):1329-1337. doi: 10.1007/s00404-020-05787-w. Epub 2020 Sep 10. Arch Gynecol Obstet. 2020. PMID: 32914222 Free PMC article. Review.
-
Human Papillomavirus Genotype Distribution among Thai Women with High-Grade Cervical Intraepithelial Lesions and Invasive Cervical Cancer: a Literature Review.Asian Pac J Cancer Prev. 2015;16(13):5153-8. doi: 10.7314/apjcp.2015.16.13.5153. Asian Pac J Cancer Prev. 2015. PMID: 26225645 Review.
Cited by
-
Transcriptionally active regions are the preferred targets for chromosomal HPV integration in cervical carcinogenesis.PLoS One. 2015 Mar 20;10(3):e0119566. doi: 10.1371/journal.pone.0119566. eCollection 2015. PLoS One. 2015. PMID: 25793388 Free PMC article.
-
The value of improving failures within a cervical cancer screening program: an example from Norway.Int J Cancer. 2014 Oct 15;135(8):1931-9. doi: 10.1002/ijc.28838. Epub 2014 Mar 20. Int J Cancer. 2014. PMID: 24615416 Free PMC article.
-
The distribution of high-risk human papillomaviruses is different in young and old patients with cervical cancer.PLoS One. 2014 Oct 8;9(10):e109406. doi: 10.1371/journal.pone.0109406. eCollection 2014. PLoS One. 2014. PMID: 25295590 Free PMC article.
-
Virus like particles as a platform for cancer vaccine development.PeerJ. 2017 Nov 15;5:e4053. doi: 10.7717/peerj.4053. eCollection 2017. PeerJ. 2017. PMID: 29158984 Free PMC article.
-
Post hoc analysis of the PATRICIA randomized trial of the efficacy of human papillomavirus type 16 (HPV-16)/HPV-18 AS04-adjuvanted vaccine against incident and persistent infection with nonvaccine oncogenic HPV types using an alternative multiplex type-specific PCR assay for HPV DNA.Clin Vaccine Immunol. 2015 Feb;22(2):235-44. doi: 10.1128/CVI.00457-14. Epub 2014 Dec 24. Clin Vaccine Immunol. 2015. PMID: 25540273 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical